Investing.com - Aerovate Therapeutics (NASDAQ: AVTE) reported first quarter EPS of $-0.67, $0.10 worse than the analyst estimate of $-0.57. Revenue for the quarter came in at $0 versus the consensus estimate of $0.
Aerovate Therapeutics's stock price closed at $21.08. It is down -21.31% in the last 3 months and up 72.08% in the last 12 months.
Aerovate Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Aerovate Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Aerovate Therapeutics's Financial Health score is "fair performance".
Check out Aerovate Therapeutics's recent earnings performance, and Aerovate Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar